Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 Billion in a Series C funding round.

TL;DR
- Isomorphic Labs raised $5 billion in Series C funding.
- The funding aims to advance drug candidates to clinical trials.
- The company uses an AI drug-design engine building on DeepMind's AlphaFold.
- Positive preclinical results have been observed in oncology and immunology.
- Deals have been struck with Eli Lilly, Novartis, and Johnson & Johnson.
- Demis Hassabis, founder and CEO, is now focusing full-time on Isomorphic Labs.
- Existing investors include Alphabet's GV and Capital G, Thrive Capital, and others.